Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 272.50p 265.00p 280.00p 272.50p 272.50p 272.50p 13,276 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 22.2 4.0 7.6 35.8 120.73

Tristel Share Discussion Threads

Showing 3176 to 3198 of 3200 messages
Chat Pages: 128  127  126  125  124  123  122  121  120  119  118  117  Older
Interim results presentation 25 Feb
melton john
Here is the study ... Wiping out MRSA: effect of introducing a universal disinfection wipe in a large UK teaching hospital Mark I. Garvey, Martyn A. C. Wilkinson, Craig W. Bradley, Kerry L. Holden and Elisabeth Holden Antimicrobial Resistance & Infection Control20187:155 hxxps://© The Author(s). 2018 Received: 27 July 2018Accepted: 3 December 2018Published: 19 December 2018 hTTps://
Simple One-Wipe System for Cleaning by Nurses is an Effective Strategy, Researchers Say Dec 19, 2018 hTTps://
Thanks guys, all very helpful - pete
Only to add that I hope and expect that the Company will continue to identify earnings enhancing opportunities. Most recently, we had the Ecomed acquisition in mid November(Benelux/France distributor). TSTL did not fund that acquisition wholly in cash. That was in order to retain a minimum cash pile, which minimum requirement I understand to be circa £3 million at any time. I can easily envisage that that minimum figure could go up, given the increase in the size of the company and the new markets it is penetrating. We were told at the October 2018 presentations that the cash balance then was £7.3 million. It has obviously reduced since then, but will now be building up again. I am not expecting another SD anytime soon.
From FY (ending June 2018) final results - "The corollary to achieving these targets is that we are likely to be highly cash generative given the operational cash requirements of the business. If the Board considers that there are no earnings enhancing opportunities to invest excess cash, a special dividend will be paid to shareholders. The Board's pursuit of these financial objectives is grounded in the belief that consistent and sustainable increases in earnings and dividends will, over time, result in share price growth." Https:// From H1 (ending Dec 2017)report - "During the first half a final dividend of 2.63 pence per share was paid, totalling £1.1m. At the period end cash was £4.9m compared to £3.9m on 31 December 2016. We will pay an interim dividend of 1.6 pence per share on 12 April 2018 to shareholders on the register on 23 March 2018, with an ex-dividend date of 22 March 2018. Our policy is to cover the dividend with earnings by at least two times and pay 40% as an interim and 60% as a final." Https://
In HY18 results - dividend cover at least 2x, with 40-60 HY/FY split. Specials will be paid "if the bored considers that there are no earnings enhancing opportunities to invest excess cash" (FY17 results).
pete, From memory: The special dividends were added when the company was recovering from a period of "not meeting expectations" ,{my best explication?}. The dividend had been sorely reduced for the period of crisis and on signs of recovery they added the special. It was a bonus, and special in that it did not need be paid, if things got bad again, without affecting the usual dividend. In one of the reports at the time {2010,2011?} their present dividend policy was laid out. AIMO, and perhaps someone else could explain it better PS: special dividends as special expenses are intended to be one off events.
Can someone pls help me out with some TSTL dividend info. A couple of years back they could be relied on to make a special divi in addition to their int and fin divis. I believe the special didn't happen last year but after searching I still can't find an announcement regarding future dividend policy. The yield is a bit low without the special. I'm sure I've missed something somewhere, so I would be grateful if someone could tell me what the current or future expectations might be. thanks, pete
... and this one NanoSeptic Continuously Self-Cleaning Surfaces The New Clean™ The New Clean means continuously self-cleaning surfaces. It means safe, non-toxic materials. It means turning dirty, high traffic public touchpoints into clean surfaces you can see. The New Clean means less worry and a healthier environment—at work, school, in healthcare and travel. NanoSeptic Skins and Mats turn dirty high traffic, public touchpoints into continuously self-cleaning surfaces. Powered by light, NanoSeptic surfaces utilize mineral nano-crystals which create an oxidation reaction stronger than bleach. Working 24/7, the surface continually oxidizes organic contaminants. Unlike traditional disinfectants and cleaners, the NanoSeptic surface uses no poisons, heavy metals or chemicals, and nothing is released from the surface since the nano-crystals are molecularly bonded to the material. hTTp://
New product range from Diversity Oxivir – High Performance Infection Prevention DEC 10, 2018 Oxivir products from Diversey deliver fast-acting, broad-spectrum disinfection against a wide range of pathogens including bacteria, viruses and yeasts. Tested to relevant EN standards, each product contains patented Accelerated Hydrogen Peroxide (AHP) as its active ingredient. This blend of commonly used, safe ingredients and low levels of hydrogen peroxide dramatically increases potency and cleaning performance. Oxivir Excel cleaner-disinfectant is designed to replace general surface cleaning products for daily tasks to provide affordable ongoing infection protection. It is fully bactericidal against multi-drug resistant organisms (MDROs) including MRSA, VRE and CRE. It is also fully viricidal against non-enveloped and enveloped viruses such as Norovirus, Influenza and HIV in 30 seconds. It is yeasticidal against Candida albicans. Non-classified, it is safe to use around patients and will not damage surfaces. Oxivir Sporicide is a ready-to-use one step hospital-grade, cleaner-disinfectant with excellent response against hard-to-kill pathogens such as C. diff, Bacillus subtilis and other MDROs in 60 seconds. Despite this efficacy its “irritant” classification is much lower than traditional alternatives. Diversey also offers disposable ready-to-use Oxivir Excel wipes and the Oxivir Spill Kit for acting quickly to contain and remove body spillages. AHP breaks down to water and oxygen shortly after use without leaving residues or stains or producing any potential respiratory irritants. Products containing AHP usually require no hazard classification. hTTps://
RNS Number : 0293K Tristel PLC 11 December 2018 AGM Statement and notice of results Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, will hold its Annual General Meeting today at 10am at Lynx Business Park, Fordham Road, Snailwell, Newmarket, Cambridgeshire CB8 7NY. At the meeting Paul Swinney, Chief Executive Officer, will provide shareholders with the following update: "We expect unaudited pre-tax profit (before share-based payments) for the first half to be no less than £2.2 million, compared to £2 million for the same period last year. The expected pre-tax profit figure takes account of the transaction costs arising from the acquisition of the Ecomed companies ('Ecomed Group') which we concluded last month; but it will include only one full month's revenue and profit contribution from them. Our integration of these new French and Benelux businesses is progressing well. "The Company is performing in line with management's expectations and our United States regulatory approvals project is progressing as planned." Paul Barnes, Interim Chairman, will add: "On behalf of my Board colleagues I would like to thank Francisco Soler, who steps down today after 25 years, for his many years of service to the Company, and to honour him with the title of Lifetime President. Francisco co-founded the business with Paul Swinney in 1993. "I step into the role of Non-Executive Chairman for one year to oversee the Board's transition at this exciting time in the Company's development and will pass the reins over to a new Chair at next year's AGM. We are making good progress in our search for new additions to our Board of Directors." The Company's unaudited interim results will be announced on Monday 25 February 2019. - excellent news .... .... IMHO
Thanks Piedro. Much water has passed under the bridge though over the ensuing six years. I would say that Byotrol,at their current price of 2.25 pence with its M/Cap of £9 million,look interesting. We should know more when the interims become available in December. Returning to the Medimark/Ecomed acquisitions,their is much significance in the comparatives.
Hi Piedro. Byotrol recently acquired Medimark Scientific in a not dissimilar transaction to Tristel's Ecomed purchase. Have you any views on BYOT ?
RNS Number : 6924H Tristel PLC 19 November 2018 Acquisition of European Distributors and Board Appointment Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces the acquisition of Ecomed Services N.V. (Belgium), Ecomed Nederland B.V. (Netherlands) and Ecomed France SARL (France), together the "Ecomed Group", and the appointment of the Ecomed's CEO, Bart Leemans, to the Tristel Board as an Executive Director. ... ...
Tristel Global@TristelGlobal Stop by our stand and meet our team in New Zealand at the Infection Prevention and Control Nurses Conference at Lower Hutt Events Centre - we'll be there until Friday 2 November, introducing Tristel Duo OPH and NCU #infectioncontrol #ophthalmology #ultrasound #IPCNC
Thanks Froddy, good idea will send message to EJ
Seems like website content and tweeting should be down to the marketing department, no?
"... HOT SHOT has now been launched in the UK and is part of a new product range, called Cache, which is dedicated entirely to surface disinfection. ..." - yawn ....., a new launch and still not on their website - they got rid of their previous ... what was his name? ... but the latest IT'er is only up to tweeting - or lost his cache AIMHO
Tristel: 2018 Profit Advances 14% (Before Hefty Share-Based Payments) As Bizarre Management Decision Delays FDA Application Once Again Leave a reply 26 October 2018 By Maynard Paton
Attended the open day in the summer when share price was close to 300p and directors took the opportunity to slot a few At 220p much more reasonably priced for a good quality small cap with opportunity to grow the business. That growth needs to come from abroad as the NHS is a difficult market for all UK suppliers aa there is moral pressure to keep prices low.
Tristel Global@TristelGlobal Visit us at #ISUOG2018 on stand 11 at Marina Bay Sands Expo and Convention Centre in Singapore. We'll be at the 28th World Congress on Ultrasound in Obstetrics and Gynaecology until Wednesday showing our Tristel Duo ULT products #infectionprevention - notice the 'Hot Shot'?
Chat Pages: 128  127  126  125  124  123  122  121  120  119  118  117  Older
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190117 04:40:45